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There is a great need for the development of vaccines that induce potent and long-lasting
protective immunity against SARS-CoV-2. Multimeric display of the antigen combined with
potent adjuvant can enhance the potency and longevity of the antibody response. The
receptor binding domain (RBD) of the spike protein is a primary target of neutralizing anti-
bodies. Here, we developed a trimeric form of the RBD and show that it induces a potent
neutralizing antibody response against live virus with diverse effector functions and provides
protection against SARS-CoV-2 challenge in mice and rhesus macaques. The trimeric form
induces higher neutralizing antibody titer compared to monomer with as low as 1μg antigen
dose. In mice, adjuvanting the protein with a TLR7/8 agonist formulation alum-3M-052
induces 100-fold higher neutralizing antibody titer and superior protection from infection
compared to alum. SARS-CoV-2 infection causes significant loss of innate cells and pathology
in the lung, and vaccination protects from changes in innate cells and lung pathology.
These results demonstrate RBD trimer protein as a suitable candidate for vaccine
against SARS-CoV-2.
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The newly emerged coronavirus SARS-CoV-2, the causativeagent of the COVID-19 pandemic has impacted the socio-economic balance worldwide. As of March 30, 2021, SARS-
CoV-2 has infected nearly 128 million people resulting in 2.7
million deaths worldwide. Thus, there is an urgent need for the
development of vaccines that elicit high titers of long-lasting
protective humoral and cell-mediated immune responses and
prevent SARS-CoV-2 infection. Recent studies using mRNA, viral
vector, protein, and DNA-based delivery platforms have shown
that vaccines that induce a strong neutralizing antibody response
against the viral spike protein can provide protection in animal
models and humans1–3. While more than 50 vaccine candidates
are currently in a clinical trial, there are only three vaccines (two
mRNA-based and one chimp adenovirus-based) that have been
approved for human use4–7. While great progress has been made
in developing vaccines that can induce a strong neutralizing
antibody response against SARS-CoV-2, it is not yet clear about
the durability of humoral immune response induced by these
vaccines, which is critical for ending the pandemic8. Towards this
end it is important to develop immunogens that induce high titer
neutralizing antibody response and combine them with adjuvants
that are known to induce long-lived humoral immunity.
The majority of COVID-19 vaccines developed so far employ
the spike protein as the antigen to generate protective immune
responses against SARS-CoV-29. Spike protein is a major virus
surface glycoprotein that engages the interaction with human
angiotensin-converting enzyme 2 (hACE2). Spike binds to
hACE2 through its receptor-binding domain (RBD) and facil-
itates virus entry into target cells9,10. On the other hand, the
S2 subunit facilitates fusion of viral envelope with cellular
membrane through the participation of heptad repeat 1 (HR1)
and heptad repeat 2 (HR2)9. Importantly, most of the neu-
tralizing antibodies generated following SARS-CoV-2 infection
and vaccination target the RBD region, and therefore, RBD
protein is a promising target to design candidate vaccines9,11.
Notably, the subunit vaccines developed using prefusion stabi-
lized full-length SARS-CoV-2 spike (S) glycoprotein in combi-
nation with saponin-based Matrix-M™ adjuvant showed
induction of strong neutralizing antibodies and protection against
SARS-CoV-2 in macaques and humans12–14. In addition to this,
monomeric RBD adjuvanted with aluminum hydroxide also
induced neutralizing antibodies against SARS-CoV-2 virus in
immunized mice, rabbits, and non-human primates and pro-
tected in vivo after SARS-CoV-2 challenge15.
Accumulating evidence suggests that multimerized antigens are
better in engaging interactions with B cell receptors thereby
facilitating generation of high-affinity antibodies compared to
monomeric antigens16–18. Multimerization of either RBD protein
or prefusion-stabilized spike (S) glycoprotein using disulfide-lin-
kages, respectively, have been shown to induce higher neutraliz-
ing antibody responses than their unmodified versions2,19. Several
strategies employing similar approaches to multimerize antigens
have been shown to enhance humoral immune responses to
target pathogens. These include the SpyCatcher-SpyTag system,
self-assembling protein nanoparticle immunogens, and several
other strategies successful in generating immune responses in
preclinical settings20–22. A significant advantage of employing
multimeric antigen display approach is that they enrich antibody
responses to specific epitopes on the target protein and induce
stronger neutralizing antibody responses with lower binding
antibodies targeting undesirable epitopes. Thus, it is important to
consider multimeric display of SARS-CoV-2 spike or RBD pro-
tein as vaccine candidates.
Besides immunogen design, adjuvants play a key role in
inducing high titer and long-lived antibody response that can
provide long-term protection23. Currently, there are only a few
adjuvants such as alum, MF59, AS03, AS04, AS01, and CpG 1018
that have been approved for human use and some promising
adjuvants are currently being tested for safety and immuno-
genicity in humans23. One such example is 3M-052, a synthetic
TLR-7/8 agonist, which is a small molecule with an 18-C fatty
acyl chain and belongs to the family of imidazoquinolines. 3M-
052 is a lipid-modified immune response modifier and was
designed to form depots of the adjuvant for a gradual and sus-
tained release for incorporation in oil-in-water emulsions or
liposomes. The intercalation of the lipid tail of 3M-052 into the
bilayer of the liposome is intended to result in a type of virus-like
particle displaying the adjuvant pharmacophore on its surface.
3M-052 maintains local adjuvant activity and does not generate
systemic responses evident with non-lipidated structures such as
R84824. In addition, this modification made 3M-052 more
amenable to incorporation in lipid-based formulations such as
nanosuspensions, liposomes, or emulsions. By utilizing this
property, to create a formulation that is more amenable for
human use, Infectious Disease Research Institute (IDRI) created a
formulation where 3M-052 was adsorbed onto aluminum
hydroxide (alum-3M-052) with the help of a phospholipid exci-
pient. Recent HIV-1 vaccination studies using alum-3M-052 with
HIV-1 clade C-derived gp140 immunogen (Env) (1086.C) in
rhesus macaques showed that 3M-052 adjuvant generates strong
bone marrow (BM)-resident long-lived plasma cells (LLPCs) and
increases the magnitude and durability of antibody responses25.
Consistent with this, we have recently shown that 3M-052
encapsulated in PLGA nanoparticles can induce strong neu-
tralizing antibodies against HIV and provide protection against a
simian and human immunodeficiency virus challenge in
macaques26,27. The positive results in macaques led to the HIV
Vaccine Trials Network currently testing the immunogenicity of
alum-3M-052 adjuvant in conjunction with HIV envelope trimer
protein in humans. These highly encouraging data strongly
support testing the utility of alum-3M-052 as an adjuvant for
COVID-19 vaccine.
Here, we evaluated the safety, immunogenicity, and protective
efficacy of RBD trimer vaccine adjuvanted with alum (a licensed
adjuvant) or alum-3M-052 in mice and rhesus macaques. Mouse
studies demonstrated that the RBD trimer protein vaccine elicits
higher neutralizing antibody response against SARS-CoV-2 virus
compared to RBD monomer. Adjuvanting the RBD trimer with
alum-3M-052 induced potent neutralizing antibody response and
provided complete protection from an infection that was superior
compared to alum. Further, studies in rhesus macaques with RBD
trimer adjuvanted with either alum or low dose alum-3M-052
induced SARS-CoV-2 neutralization titers with a median of 800
and protected from virus replication in the lower respiratory tract
following intranasal and intratracheal (IT) SARS-CoV-2 chal-
lenge. In addition, vaccination reduced lung pathology with no or
low anamnestic innate, T cell, and antibody responses compared
to control macaques. These data support the utility of RBD trimer
protein as a potential vaccine candidate against SARS-CoV-2
infection.
Results
RBD trimer protein binds to ACE2 with 500-fold higher affi-
nity compared to RBD monomer. To express a trimeric form of
RBD protein we fused amino acid residues 319–541 of SARS-
CoV-2 spike protein to the trimerization domain of T4 (Fig. 1A).
To promote the secretion of the protein we added the tissue
plasminogen activator (tPA) signal sequence at the N-terminus.
This fusion protein was expressed under the control of CMV
promoter with intron A. We confirmed the expression of the
fusion protein using flow cytometry (Fig. 1B) in 293T cells
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transfected with DNA. We then expressed the protein in 293F
cells using the transient transfection with DNA and purified from
the supernatants by first binding to Con A agarose followed by
size-exclusion chromatography (SEC). We found four peaks on
SEC and determined peak 3 to be the RBD trimer based on
expected size and Western blotting under non-reducing condi-
tions (Fig. 1C). The typical yield of the protein was around 2.2
mg/liter which can be greatly improved by using a stable cell line
constitutively expressing the protein and tag-based purification
system. To determine the proper folding of the trimer we mea-
sured its binding to human ACE2 using biolayer interferometry
(BLI) (Fig. 1D). As a control, we used RBD monomer protein. We
observed that RBD trimer binds to ACE2 with very high affinity
(KD of 0.035 nM) and this was about 500-fold higher compared
to RBD monomer (KD of 19 nM) (Fig. 1D). These results
demonstrated that RBD trimer protein fused to T4 trimerization
domain formed trimers, folded properly, and binds to hACE2
with very high affinity.
RBD trimer adjuvanted with Alum-3M-052 induces a robust
neutralizing antibody response in mice. We next determined
the immunogenicity and protective potential of RBD trimer
protein in BALB/c mice (Fig. 2A). For these experiments, we
compared two adjuvants, alum and alum-3M-052. In the initial
experiments we vaccinated mice with 10 µg of protein on weeks 0
and 4, and measured antibody responses on week 3 (prime) and
week 6 (boost). Following prime, the alum-3M-052 group
induced RBD-binding antibody with a titer of 1.7 × 104 in serum
(Fig. 2B). However, these responses were close to the level of
detection in the alum group. Following the boost, these titers
increased by 100-fold in both groups with titers reaching 1.7 × 106
in the alum-3M-052 group and 1.9 × 104 in the alum group
(Fig. 2B). These results demonstrated that RBD trimer adjuvanted
with alum-3M-052 induced a robust binding antibody response
following two immunizations that is 100-fold higher compared to
the response induced by alum. Importantly, the RBD trimer-
induced antibody also showed robust neutralizing activity against
the live SARS-CoV-2 virus with a geometric mean of 7000 (range
1010–17,628) in the alum-3M-052 group (Fig. 2C). Consistent
with a lower RBD-binding titer, the neutralizing antibody titer in
the alum group was 100-fold lower with a geometric mean of 66.
The RBD binding titer correlated directly with the neutralizing
antibody titer (Fig. 2D). The ratio of IgG2a to IgG1 of RBD
binding antibody at 2 weeks post-boost was significantly higher in
the alum-3M-052 group compared to the alum group demon-
strating a Th1-biased response in the former compared to the
latter (Fig. 2E).
RBD trimer adjuvanted with Alum-3M-052 induces higher
neutralizing antibody response compared to RBD monomer
and protects from SARS-CoV-2 infection in the lungs of mice.
We next compared the immunogenicity of RBD trimer and
monomer using the two adjuvants. For these experiments, we
used 1 µg of protein, since high doses of protein can mask dif-
ferences in immunogenicity. Following prime, the low titer of
RBD-binding antibody (geometric mean of 103) was observed
only in the trimer/alum-3M-052 but not in trimer/alum and
monomer with either adjuvant (Fig. 2F). Following boost, the
binding antibody titers were high in (trimer and monomer) alum-
3M-052-adjuvanted animals but not in alum-adjuvanted animals
Fig. 1 RBD trimer protein binds to ACE2 with 500-fold higher affinity compared to RBD monomer. A Schematic representation of DNA/RBD trimer
(pGA8/RBDtri). DNA/RBD trimer encodes for SARS-CoV-2 RBD from amino acid residues 1–223 (represents amino acid residues 319–541 of SARS-CoV-2
spike protein) with the T4 trimerization domain at C-terminus and tPA at N-terminus. B Representative flow plots showing the expression of RBD trimer by
DNA/RBD trimer. C Size-exclusion chromatogram showing RBD trimer peak (left) and western blotting analysis (right) confirms RBD trimer protein
expression by plasmid construct. D Bio-Layer Interferometry (BLI) sensograms of the binding of DNA/RBD trimer versus monomer to immobilized Fc-
human ACE2. The traces represent BLI response curves for SARS-CoV-2 proteins serially diluted from 300 to 9.375 nM, as indicated. Dotted lines show
raw response values, while bold solid lines show the fitted trace. The data was globally fit using a 1:1 binding model to estimate binding affinity. The
experiments related to B–D were repeated twice and representative data are shown.
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(Fig. 2F). Further, the binding titer in the trimer/alum-3M-052
group (geometric mean of 1.7 × 105) was 2-fold higher (not sig-
nificant) compared to monomer/alum-3M-052 group (8 × 104).
However, the neutralization titer against the live virus was mostly
observed in the trimer/alum-3M-052 group and this was sig-
nificantly higher than all other groups including monomer with
alum-3M-052 (Fig. 2H). To determine the protective potential, we
challenged mice intranasally with a mouse-adapted SARS-CoV-2
MA10 virus28 and measured viral titer in the lungs at day 2 (3 out
of 5 mice in each group) and weight loss until day 5 (2 out of 5
mice in each group) (Fig. 2I, J). As expected, all control animals
showed a very high viral titer of about 107 pfu/lung on day 2 and
exhibited weight loss from days 3 to 5. Impressively, all mice in
the trimer/alum-3M-052 group were completely protected from
infection and did not show weight loss. 2 out of 3 mice in the
monomer/alum-3M-052 group were also protected but showed a
transient weight loss on day 3. In contrast, all but one animal in
the alum-adjuvanted group was infected, showed high virus
replication, and showed some weight loss. These results demon-
strated that low dose (1 µg) RBD trimer protein adjuvanted with
alum-3M-052 induces neutralizing antibodies against SARS-CoV-
2 and provides protection against intranasal SARS-CoV-2 chal-
lenge in mice.
RBD trimer protein induces both neutralizing and non-
neutralizing antibodies with effector function and Th1-baised
CD4 T cells in macaques. To further investigate the translational
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Neutralization, 1ug dose, Wk 6
Fig. 2 RBD trimer adjuvanted with Alum-3M-052 induces a robust neutralizing antibody response and provides protection against SARS-CoV-2
challenge in mice. A The experimental schedule representing the timeline for the immunizations (study 1) and SARS-CoV-2 (MA10) challenge (study 2).
Each immunization group has five animals (n= 5 mice per group). Study 1 (B–E): 6-week-old female BALB/c mice were immunized with RBD trimer (10
µg/mice) either with Alum (blue) or with 3M-052-Alum (red) via intramuscular route at weeks 0 and 4. B Endpoint IgG titers against SARS-CoV-2 RBD
measured in serum collected at week 2 post-prime and week 2 post-boost immunizations. Each sample was analyzed in duplicates. C Neutralization titer
against live mNeonGreen SARS-CoV-2 virus. Each sample was analyzed in duplicates. D Correlations between neutralization titer and ELISA binding titers
of RBD trimer antigen either with Alum (blue) and 3M-052 (red) adjuvants. The Spearman rank test was used to perform correlation analysis. E Bar graph
shows the ratio of SARS-CoV-2 RBD-binding IgG2a and IgG1 antibody measurements. Each sample was analyzed in duplicates. Study 2 (F–J): Six-week-old
female BALB/c mice were immunized either with RBD trimer or RBD monomer (1 µg/mice) adjuvanted either with Alum (blue) or with 3M-052-Alum
(red) via intramuscular route at weeks 0 and 4. Immunized mice were mock-infected, infected with 105 PFU SARS-CoV-2 MA10. F–G Endpoint IgG titers
against SARS-CoV-2 RBD measured in serum collected at week 2 post-prime (F) and week 2 post-boost (G) immunizations. Each sample was analyzed in
duplicates. (H) Neutralization titer against live mNeonGreen SARS-CoV-2 virus. Each sample was analyzed in duplicates. Circles indicate week 2 post-
prime and filled triangle indicates week 2 post-boost immunizations. (I-J) Lung SARS-CoV-2 (MA10) viral titers of vaccinated animals compared to
unvaccinated (I) and percent starting weight (J). In both studies, the black, blue, and red circles indicate naïve controls, alum, and alum-3M-052,
respectively. Data are mean ± SEM. A two-sided Mann–Whitney U-test was used to compare between groups, *p < 0.05 and **p < 0.01.
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immunized two groups of rhesus macaques intramuscularly with
30 µg of protein on weeks 0 and 4 (Fig. 3A). One group (n= 5)
was adjuvanted with alum (1 mg) and the other (n= 4) with
alum-3M-052 (1 mg alum, 10 µg of 3M-052). The 10 µg dose of
3M-052 was significantly lower than the dose of 70 µg that has
been used in monkeys so far25. We used the 10 µg dose since an
ongoing human study with HIV envelope is testing 5 µg. Two
weeks following prime, low titers of RBD-binding antibody were
observed in both groups that were either maintained or mar-
ginally increased by 4 weeks (Fig. 3B). However, in contrast to
what was observed in mice, the responses were comparable
between the two adjuvant groups. This could be due to the use of
a lower dose of 3M-052 compared to previous studies that
showed superior humoral immune responses by 3M-052
compared to alum25,29,30. Following the boost at week 6 (Fig. 3C),
both groups showed significantly higher neutralizing antibody
titers against live SARS-CoV-2 with geometric mean values of 367
and 778 in the alum and alum-3M-052 groups, respectively
compared to controls. Of the 9 animals, 3 animals had a titer
>1000 and there was no difference between the two groups,
presumably due to the small group size. By week 8 (day of the
challenge), the neutralization titer was maintained (<2-fold
decline) in 5 animals and declined by 2.5-fold in 3 animals and 9-
fold in one animal. At this time, the titer in the alum-3M-052
group was 2.4-fold higher compared to the alum alone group,
though not significantly different. As observed with mouse sera,
the RBD-binding titer correlated directly with SARS-CoV-2
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Fig. 3 RBD trimer induces both neutralizing and non-neutralizing antibodies with effector function in macaques. A Schematic showing timeline of RBD
trimer vaccination, SARS-CoV-2 challenge, and sample collection for the macaque study. Rhesus macaques (n= 9) were distributed into two experimental
groups to immunize with RBD trimer (30 µg/dose) adjuvanted either with alum (blue) (n= 5) or with alum-3M-052 (red) (n= 4) via intramuscular route
at weeks 0 and 4. Seven unvaccinated animals served as controls. Vaccinated and control animals were challenged intranasally (IN) and intratracheally (IT)
with SARS-CoV-2 at 4 weeks following boost. B Endpoint IgG titers against SARS-CoV-2 RBD measured in serum collected before vaccination (Prevac) and
at weeks 2, 4, 6, and 8 after priming immunization. Each sample was analyzed in duplicates and repeated twice. C Neutralization titer against live
mNeonGreen SARS-CoV-2 virus in serum. Each sample was analyzed in duplicates and repeated twice. D Correlation analysis between SARS-CoV-2
neutralization titer and RBD binding titers. The Spearman rank test was used to perform correlation analysis. Dotted lines reflect the limit of detection.
E Radar plot showing SARS-CoV-2 RBD-specific systems serology measurements (antibody isotypes and subclass, FcγR binding, and antibody-dependent
effector functions) at pre-vaccination and week 6 post-vaccination time points. F Correlation matrix analysis between antibody-dependent functions
(neutralization, ADCP, ADNP, and ADCD) and SARS-CoV-2 RBD-specific antibody isotypes, and FcγR binding at 2 weeks post the boost. The color
refers to r value scale (−1 to 1) shown on the right. The number in each cell indicates the actual r value and the stars represent p-values. G IFNγ+, TNFα+,
IL-2+, IL-21+, IL-4+, and IL-17+ CD4+ T cells specific to total S protein (sum of response to peptide pools S1 and S2) in blood at week 5 post boost.
Box and whiskers (min to max) plot showing all the data points in each group. Individual animals were indicated with circles. p-values were calculated
using a Mann–Whitney test, represent the difference between pre-vaccination and respective post-vaccination value. ∗p < 0.05; **p < 0.001; and
***p < 0.0001.
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We next compared various parameters including IgG sub-
classes, IgA, IgM, binding to different FcγRs, and functions such
as antibody-dependent cellular phagocytosis (ADCP), antibody-
dependent neutrophil phagocytosis (ADNP), and antibody-
dependent complement deposition (ADCD) (Fig. 3E, Fig. S1).
As expected, the IgG response was the most dominant, IgA
responses were present at very low levels and the IgM response
was negative. Among the IgG subclasses, IgG1 was the most
dominant and IgG2, IgG3, and IgG4 were present at low levels.
Among the effector functions tested, the ADCD activity was high
and the ADCP and ADNP activities were present at very low
levels. The vaccine-induced antibody also showed greater binding
to FcγR3A and no binding to FcR2A-1, FcR2A-3, and FcR2A-4.
The neutralizing activity showed a significant correlation with
spike-specific IgG subclass and IgA binding, and ADCD activity
(Fig. 3F). Similarly, all three effector functions correlated with
IgG-binding activity and with each other. As with the binding
and neutralizing activities, there was no difference between the
two vaccine groups. Overall, these results show that RBD trimer
protein-induced antibodies possess neutralizing activity with
diverse effector functions. We evaluated the T cell responses
induced by vaccination by stimulating peripheral blood mono-
nuclear cells with overlapping peptide pools specific to RBD
protein and intracellular cytokine staining assay (Fig. 3G). After
the 2nd immunization we observed low frequencies of CD4 T cells
producing IFNγ, TNFα or IL-2 but not IL-4 and IL-17 suggesting
a Th1-biased response. However, there was no difference between
the two groups. We did not observe any detectable spike-specific
CD8 T cell response.
Alum-3M-052 induces better innate activation compared to
alum in macaques following vaccination. The innate immune
system plays an important role in modulating the immune
responses mediated by adjuvants. Therefore, we measured
the early innate immune responses in the blood of vaccinated
animals in terms of changes in cell frequencies (Fig. 4A, B)
and their activation based on CD86 expression (Fig. 4C) at Day 1
post primary vaccination, as we showed previously that most
changes in DC frequencies and activation occur at this time point
following vaccination with alum or TLR7/8 agonist R84829. We
focused our analyses on three subsets of monocytes (classical,
intermediate and non-classical), NK cells, three subsets of DCs
(plasmacytoid, BDCA-1+ and CD11c+) and two subsets of
myeloid-derived suppressor cells (MDSC) (polymorphonuclear,
PMN-MDSC and monocytic, M-MDSC). Vaccination with alum
and alum-3M-052 induced differential responses. In particular,
we observed that the frequency of classical monocytes decreased
and plasmacytoid DC (PDC) increased in alum-3M-052 group
compared to alum group, while their pre-vaccination frequencies
were comparable. Frequency of M-MDSC increased and NK cells
decreased post-vaccination in both the groups, while the decrease
in NK cells was profound in alum-3M-052 group compared to
alum group.
With respect to activation, alum-3M-052 caused higher
activation of intermediate monocytes, PDC, BDCA-1+ DC,
MDC, and PMN-MDC (only a trend) whereas alum primarily
activated PDC. In addition, the activation of classical monocytes
decreased in the alum group. Overall, alum-3M-052 showed
activation of monocytes and myeloid DCs post- vaccination while
both adjuvants showed activation of PDC. While there was no
significant difference in the antibody titer between alum and
alum-3M-052 adjuvanted groups in the short term, it is
conceivable that the superior innate activation observed in the
alum-3M-052 group could lead to induction of long-lived
antibody responses in this group.
RBD trimer protein vaccination provides protection from
SARS-CoV2 infection and replication in the lungs of maca-
ques. To evaluate vaccine efficacy, we challenged vaccinated
rhesus macaques with SARS-CoV-2 via intranasal and IT routes
at week 8 (4 weeks after the boost). Seven animals that did not
receive SARS-CoV-2 vaccine served as controls. Following
intranasal and IT challenge we monitored for sub-genomic viral
RNA to measure replicating virus in the lung (BAL) and
nasopharynx on days 2, 4, 7, and 10 (day of euthanasia) (Fig. 5).
On Day 2, 6 out of 7 controls tested positive for virus in BAL
(Fig. 5A, B), and 4 out of 7 tested positive in the nasopharynx
(Fig. 5D, E). The only animal (RGa17) that scored negative for
virus in BAL showed very high virus replication in the naso-
pharynx (2 × 107 copies/ml) indicating that all animals were
productively infected. The viral RNA levels were variable and
ranged from 2 × 102 to 2 × 107 copies/ml. By Day 4, the viral
titer decreased in some animals and increased in others and
showed a decline by Day 7 in all animals. On Day 10, 2 out of 7
controls still scored positive for virus in BAL and 1 out of 7
controls scored positive for virus in the nasopharynx. In con-
trast, 3 out of 5 alum vaccinated, and 3 out 4 alum-3M-052
vaccinated animals scored negative for virus in BAL at all times
tested. By Day 10, all vaccinated animals tested negative for
virus in BAL (Fig. 5B). The area under the curve (AUC) of viral
load between Day 0–10 showed significantly lower viral load in
vaccinated animals compared to controls (Fig. 5C). A similar
protection from infection or viral control was also observed in
the nasopharynx of vaccinated animals except that AUC was
not significantly different compared to control animals
(Fig. 5D–F). These results demonstrated that RBD trimer
protein vaccination provides protection from SARS-CoV-2
infection and/or replication in the lungs. We performed cor-
relations between Day 2 viral RNA titer in the BAL or naso-
pharynx with various antibody functions at the peak of vaccine
response (2 weeks post the 2nd protein). We found moderate
(r > 0.5, p < 0.1) inverse correlations (better protection) with
neutralizing antibody titer, RBD/spike specific ADCP, ADCD,
IgA, and FcR3A-binding activities suggesting that multiple
antibody functions contributed to the protection and viral
control (Fig. S2).
To assess lung pathology, we analyzed multiple regions of
upper, middle, and lower lung lobes at euthanasia. Lung
pathologic analyses and scoring (considering severity and number
of affected lobes) were performed by two independent patholo-
gists in a blinded fashion. Consistent with early virus control in
the lungs vaccinated animals also showed lower lung pathology
scores compared to control animals (Figs. 5G, S3, S4, Table S1).
The pathology score in the alum-3M-052 animals was signifi-
cantly lower compared to controls, however, in the alum group
the difference was not significant. In addition, animals in the 3M-
052-Alum group showed a trend towards lower lung pathology
compared to animals in the Alum alone group. Overall, these data
supported a beneficial role of RBD trimer protein vaccination in
reducing lung pathology, especially in the alum-3M-052 group.
We also performed histopathologic examination of various other
tissue samples including nasal turbinates, trachea, tonsils, hilar
lymph nodes, spleen, heart, brain, gastrointestinal tract (stomach,
jejunum, ileum, colon, and rectum), and testes. We did not
observe significant histological lesions in upper respiratory tract
tissues (nasal turbinates, trachea) and other examined tissues in
control and vaccinated animals.
To understand the anamnestic expansion of antibody and
T cells post-infection, we measured binding antibodies to RBD in
serum on Days 0, 4, 7, and 10; and T cells in the blood at Day 10,
following virus challenge. Five out of the 7 control animals
became seropositive (RBD binding titer >2 fold compared to
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pre-infection) by Day 10 with a geometric mean titer of 651 that
was 200-fold lower compared to the titer in vaccinated animals
(Fig. 5H). In contrast, the RBD-binding antibody either stayed
constant or decreased in all vaccinated animals except one animal
each in alum and alum-3M-052 groups that showed a 2.4- and 7-
fold increase compared to pre-infection titer (Fig. 5H). These
were the same two animals that were positive for virus in the BAL
on Day 2 and in nasopharynx on Day 7 suggesting an anamnestic
expansion of the antibody response following infection. Con-
sistent with high virus replication, the control animals developed
IFNg+ CD4 and CD8 T cell responses at Day 10, and most of the
response was targeted against S1 and nucleocapsid (NC) proteins
(Fig. 5I). Consistent with better protection and viral control, the T
cell response in vaccinated animals was either low or negative and
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was significantly lower compared to controls (Fig. 5I). In
conclusion, these results demonstrated that RBD trimer vaccina-
tion provides significant protection from infection and pathology
in the lungs. Consistent with similar binding and neutralizing
antibody response post-vaccination there was no significant
difference between the two adjuvants at the dose tested in
macaques.
RBD trimer vaccination protects from infection-induced
immune abnormalities in the lung. To get further insights on
the influence of infection and viral replication on innate immune
cells, T follicular cells (Tfh), and B cells in the lung, we deter-
mined the frequency of various innate immune cells in BAL
longitudinally, and the frequency of germinal center (GC) Tfh
and GC-B cells in lung draining hilar lymph node on Day 10
Fig. 4 Alum-3M-052 induces better innate activation compared to Alum in macaques. A Flow cytometry gating strategy used to identify various innate
cells in blood. Live cells were selected using live/dead marker and CD3+ and CD20+ cells were excluded. Then, different innate cells were defined using
the following combination of markers. B and C Frequencies of various innate cells (B), Monocytes (HLA-DR+)—classical (CD14+), intermediate (CD14+
and CD16+) and non-classical (CD16+); PDCs (HLADR+ CD14− CD16− CD123+ BDCA1−); BDCA1+ DC (HLADR+ CD14− CD16− CD123− BDCA1+);
MDCs (HLADR+ CD14− CD16− CD123− CD11c+); M-MDSC cells (HLADR− CD14+ CD11b+); PMN-MDSC cells (HLADR− CD14− CD11b+) and NK cells
(HLADR− NKG2A+); and CD86+ activation (C). NK natural killer cells, PDC plasmacytoid dendritic cells, MDC myeloid-derived dendritic cells, myeloid-
derived suppressor cells (MDSC), polymorphonuclear (PMN)—MDSC, and monocytic (M)—MDSC. Groups were color-coded; Alum: Blue, Alum-3M-052:
Red. Bars and columns show mean responses in each group ± SEM; Statistical significance was measured using two-tailed paired t-test for comparisons
within the group and two-tailed un-paired parametric t-test for comparisons between the groups. Asterisks denote statistical significance ∗p < 0.05
and **p < 0.01.
Fig. 5 RBD trimer protein vaccination provides protection from SARS-CoV2 infection and replication in the lungs in macaques. A–F SARS-CoV-2
subgenomic viral RNA copies/ml in the BAL fluids (Lungs) (A–C) and nasal fluids (D–F) on days 2, 4, 7, and 10 (day of euthanasia) post infection.
Geomean for each group (A, D), data for individual animal (B, E) and the area under the curve (AUC) (C, F) are shown. The AUC was calculated based on
viremia from Day 0 to Day 10. Comparison between non-vaccinated (n= 7) and vaccinated (n= 9) macaques was calculated using Student’s t-test
(unpaired, two-tailed). G Lung pathology score at Day 10 post-infection. Hematoxylin and Eosin-stained lung sections were used to analyze tissue structure
and cell infiltration. The representative images for each animal presented in Fig. S2. See Table S1 for additional details. H SARS-CoV-2 RBD-specific serum
IgG responses in serum following challenge. Each sample was analyzed in duplicates and repeated two independent times. I IFNγ+CD4+ and CD8+
T cells in blood at Day 10 post-infection after re-stimulation with peptide pool specific to indicated protein. S1, S1 region of spike; S2, S2 region of spike;
NC, nucleocapsid; Sum, total response (S1+ S2+NC). Bars and columns show mean responses in each group ± SEM; Mann–Whitney test: ∗p < 0.05,
and **p < 0.001. Dotted lines reflect the limit of detection.
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(Figs. 6 and S5). For innate cells we studied macrophages, three
subsets of DC (PDC, BDCA-1+, and MDC), and NK cells on
Days 4, 7, and 10. Among the total cells, the macrophages
represented the majority with frequencies ranging from 10% to
70%, and the DC (HLA-DR+ cells without macrophages) and NK
cells represented 0.1–1% (Fig. 6A). In controls, the frequency of
macrophages increased from Day 4 to Day 7 and returned to Day
4 values by Day 10. However, the frequency of DCs declined
sharply from Day 7 to Day 10, and the frequency of NK cells
showed a gradual increase by Day 10. In vaccinated animals,
however, the frequencies of all innate cells stayed relatively stable
with occasional blips (Fig. 6A). In particular, the two vaccinated
animals that showed clear virus replication in BAL showed an
increase in the frequency of macrophages and DCs from Day 4 to
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Day 7 and a decline from Day 7 to Day 10. The control animals
showed significantly higher frequencies of PDC on Day 4 and
macrophages on Day 7 compared to vaccinated animals. Corre-
lations with Day 2 viral load revealed a negative association with
macrophages on Day 4 (Fig. 6B) and a positive association with
DCs on Day 7 (Fig. 6C). Consistent with a sharp decline in DCs
from Day 7 to Day 10 in controls, the DC frequencies on Day
10 showed a negative association with Day 2 viral load (Fig. 6D).
These results suggested that early (Day 2) high virus replication in
the lungs may lead to early depletion of macrophages but the
expansion of DCs, in particular PDC. Importantly, they show a
gradual loss of DCs by Day 10 (Fig. 6E) despite most animals
being negative for viruses demonstrating severe innate immune
perturbations in the absence of vaccination. They also demon-
strated that the vaccinated animals do not show significant
changes for various innate immune cells consistent with better
protection and viral control in these animals.
In the hilar lymph node at Day 10, we observed higher frequency
of GC-TFH in the controls compared to the Alum-3M-052 group
(Fig. 6F). However, the frequency of GC-Tfh was not significantly
different between the control and Alum group. Similarly, the
frequency of CXCR3 expression on the GC-Tfh (an indicator of
pro-inflammatory environment) was also higher in the controls
compared to Alum-3M-052 group but not the Alum group (Fig. 6F)
and showed a direct correlation with Day 2 viral load in BAL
(Fig. 6H). These observations suggested high viral antigen present in
lymph node of control animals than vaccinated animals. Overall,
these data indicated that vaccination lowers viral replication in the
lungs and protects lungs from infection-induced pathology.
Discussion
Effective vaccines that induce long-lived protective immunity are
urgently needed to control the SARS-CoV-2 spread and the
current pandemic31,32. Here, we designed and developed an RBD
trimer protein and tested its immunogenicity and efficacy using
two adjuvants in mice and macaques. Our results showed that
RBD trimer induces a potent neutralizing antibody response with
multiple antibody effector functions such as ADCD, ADCC, and
ADCP, and provides protection against the SRAS-CoV-2 chal-
lenge in mice and macaques. They also showed that RBD trimer
vaccination protects from lung pathology induced by SARS-CoV-
2 infection. RBD trimer vaccinations induced Th1-biased CD4 T
cell response which may be important for control of SARS-CoV-2
in humans33,34. As expected with protein-based vaccines, we did
not observe the induction of CD8 T cell responses. As with most
previous COVID-19 vaccine studies in macaques, the protection
from infection and virus replication was mainly evident in the
lower respiratory tract (lungs) (Fig. 5A–C) and not in the upper
respiratory tract (nasopharynx) (Fig. 5D–F)1,35,36. However, the
viral replication is more variable in the nasopharynx and there-
fore larger group sizes are required to make definitive conclusions
about vaccine efficacy on virus control in this compartment.
Nevertheless, the neutralization titer, antibody effector functions,
and protection we observed in this study are strong and merit
further testing of RBD trimer as a potential vaccine immunogen
for SARS-CoV-2.
Our results revealed that RBD trimer elicits higher neutralizing
antibody responses compared to RBD monomer at 1 μg dose,
which is 10-times lower than what is normally used in mice. It
was interesting to note that the binding titer was comparable
between the two immunogens and yet the neutralization titer was
significantly higher in the RBD trimer group. We think the
superior immunogenicity of RBD trimer can be attributed to the
multimeric nature of the protein that resulted in higher activation
and selection of high-affinity B cells. It is also possible that the
specificity of neutralizing antibodies induced by the RBD trimer
may be different from RBD monomer. Future studies will
investigate these aspects and will determine the cross-reactivity of
the induced antibody against newly emerging variants of SARS-
CoV-2. Along the same lines, recent studies using dimeric37 or
multimeric display38 of RBD protein have shown superior
immunogenicity compared to RBD monomer. It is also important
to note that the ability to use lower doses of protein will have
important implications for human translation potential.
Multiple studies have used RBD-based immunogens as a vac-
cine for COVID-19 and tested for immunogenicity in animal
models15,19,37,39–41. Most of these studies used RBD monomers as
an immunogen, one study each used RBD dimers37 or RBD
60mer displayed on a nanoparticle19 as immunogen. Among
these only one study investigated the protection against SARS-
CoV-2 challenge in rhesus macaques15. While it will be infor-
mative to compare the immunogenicity and protection that we
observed in this study with other RBD and non-RBD-based
vaccine candidates, we think one needs to be careful since dif-
ferent studies used different neutralization assays that can provide
different results. For example, one study reported that the
neutralization titer measured using pseudovirus assay is nearly
10-times higher than the titer measured using the live virus
neutralization42. In addition, some studies reported 50% neu-
tralization titer and others 80–90%. Similarly, for protection
studies, different stocks and doses of viruses, and species of
macaques have been used. Importantly, most non-human pri-
mate studies used small group sizes (5–7 animals/group) and
variability between each animal for neutralization titer can make
comparisons harder. However, the emerging theme is that mul-
timeric immunogens are superior to monomeric immunogens in
inducing neutralizing antibody response against SARS-CoV-2.
Our mice studies clearly demonstrated that alum-3M-052 is
superior to alum in inducing neutralizing antibody responses and
protection. In mice we used a dose of 1 μg based on the previous
titration in mice with another antigen. However, in rhesus
macaques, we did not observe a significant difference between
Fig. 6 Immune responses in lungs and hilar lymph-node of rhesus macaques, post SARS-CoV-2 challenge. A Following SARS-CoV-2 infection, BAL was
collected on Days 4, 7, and 10, and frequencies of macrophages, total DCs, NK cells, PDCs, BDCA-1 DCs, and MDCs were measured. Gating strategy to
identify innate cells in BAL fluid. Live cells were selected using live/dead marker and CD3+ and CD20+ cells were excluded. Then, different innate cells
were defined using the following combination of markers: Macrophages (HLADR+ CD163+); PDCs (HLADR+CD163−CD123+ BDCA1−); BDCA1+ DC
(HLADR+ CD163− CD123− BDCA1+); MDCs (HLADR+CD163−CD123−CD11C+) and NK cells (HLADR− NKG2A+). B–D Correlation analysis between
Day 2 BAL viral loads (VL) and Day 4 macrophage frequencies (B); Day 2 BAL VL and Day 7 total DC frequencies (C); Day 2 BAL VL and Day 10 total DC
frequencies (D). E Total DC frequencies in BAL fluid at Day 10 post-challenge in control, alum (Blue), and alum-3M-052 (Red) groups. F and G On Day 10
(at euthanasia), GC-Tfh (F) and CXCR3 GC-Tfh (G) cells were analyzed in hilar LN. Left: Representative flow plots; Right: Summary of data for all animals.
CD3+CD4+CD8-CXCR5highPD-1high cells defined as GC-Tfh. H Correlation between Day 2 BAL VL and Day 10 HILAR LN CXCR3 GC-Tfh. The Spearman
rank test was used to perform correlation analysis. NK, Natural killer cells. PDC, Plasmacytoid dendritic cells. MDC myeloid-derived dendritic cells, LN
lymph node. Statistical differences between the groups and within the groups were analyzed using unpaired parametric t-test and paired-parametric t-test
respectively. ∗p < 0.05, and **p < 0.001.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-23942-y
10 NATURE COMMUNICATIONS |         (2021) 12:3587 | https://doi.org/10.1038/s41467-021-23942-y | www.nature.com/naturecommunications
alum and alum-3M-052 although there was a trend for better
immune and protection outcomes with alum-3M-052. The non-
significant differences between 3M-052 Alum and Alum alone
could be due to an ineffective dose of 3M-52 in monkeys or the
small sample size of animals being used. We think it is important
to determine the optimal dose of alum-3M-052 for non-human
primates and humans. The 10 µg dose of alum-3M-052 we used
in our rhesus macaque study is 7.5 times lower than the dose we
used for nanoparticle (NP) encapsulated 3M-052 (70 µg, NP-3M-
052), which showed induction of high titer and persisting anti-
body response at least for one year against HIV-1 envelope
protein and provided protection in rhesus macaques12–14.
In addition, NP-3M-052 induced the generation of plasma cells
in bone marrow that are critical for the generation of persisting
antibody titers. We did not measure plasma cells in bone marrow
in the current study. However, given the activation of DCs and
monocytes following vaccination in the alum-3M-052 adjuvanted
group we predict that vaccination would induce plasma cells in
the bone marrow and that will lead to the generation of long-lived
neutralizing antibody response against SARS-CoV-2. Considering
the protection induced by alum-3M-052 both in mice and
macaques, our study supports further testing of alum-3M-052 as
a potential adjuvant for SARS-CoV-2 protein-based vaccines.
We monitored the frequency of innate cells in BAL during the
course of infection to understand the influence of virus replica-
tion in unvaccinated controls and how these changes relate to
protection in vaccinated animals. Recent studies on SARS-CoV-2
infected rhesus macaques in unvaccinated animals43,44 showed
significant changes in frequencies of macrophages after infection.
These studies also showed an increase in NKG2A+ NK cells43,44
and PDC43,44 post-infection. Consistent with these observations,
in our study, we saw an increase in the frequency of NKG2A+
cells and higher PDCs during the early phase of infection (day 4
post-infection) in control animals, while vaccinated animals were
relatively stable. Similar observations of decreased macrophages
and increased PDCs in BAL were also reported during human
infection45. Overall, these observations in BAL suggested rela-
tively low infection and virus replication in vaccinated animals
compared to control animals.
In conclusion, we demonstrated the potential benefits of RBD
trimer as an immunogen for COVID-19 vaccine using mice and
macaque models. Future studies will investigate the durability of
the vaccine-induced immune responses and what parameters lead
to protection.
Methods
Cells and viruses. Human embryonic kidney (HEK)-293T cells, and Vero cells
were obtained from ATCC. SARS-CoV-2 (icSARS-CoV-2) virus was obtained from
BEI resources and grown in Suthar’s laboratory at the Emory University.
mNeonGreen SARS-CoV-2 (2019-nCoV/USA_WA1/2020) virus was produced by
Pei Yong Shi’s laboratory at the University of Texas46. The infectious clone SARS-
CoV-2 (icSARS-CoV-2) was propagated in VeroE6 cells (ATCC) and sequenced46.
The titer of SARS-CoV-2 viruses (icSARS-CoV-2 and 2019-nCoV/USA_WA1/
2020) using VeroE6 cells. VeroE6 cells and HEK-293T cells were cultured in
complete DMEM medium consisting of 1× DMEM (Corning, Cellgro), 10% fetal
bovine serum (FBS), 25 mM HEPES buffer (Corning Cellgro), 2 mM L-glutamine,
1 mM sodium pyruvate, 1× non-essential amino acids, and 1× antibiotics. Viral
stocks were stored at −80 °C until further use.
Animal models. Specific-pathogen-free (SPF) 6–8-week-old female BALB/c mice
(00065 strain) were obtained from Jackson Laboratories (Wilmington, MA, USA)
and housed in the animal facility at the Yerkes National Primate Research Center
of Emory University, Atlanta, GA. Male Indian rhesus macaques (Macaca mulatta),
3–4.5 years old, were housed in pairs in standard non-human primate cages and
provided with both standard primate feed (Purina monkey chow) fresh fruit, and
enrichment daily, as well free access to water. Immunizations, blood draws,
and other sample collections were performed under anesthesia with ketamine
(5–10 mg/kg) or telazol (3–5 mg/kg) performed by trained research and
veterinary staff.
Construction and characterization of DNA/RBD trimer plasmid. The plasmid
containing amino acids residues 319–541 of SARS-CoV-2 spike protein fused to
His tag was obtained from BEI resources (Cat# NR-52309). The plasmid expressing
RBD monomer (DNA/RBD mono) was generated by cloning insert in pGA8 vector
between NheI and AvrII restriction enzyme sites. Further, the plasmid expressing
RBD trimer proteins (DNA/RBD tri) was generated by placing T4 trimerization
sequence (GYIPEAPRDGQAYVRKDGEWVLLSTFL) at the C-terminus without
His tag using In-Fusion cloning technology (Takara). Both plasmids contain the
TPA signal sequence under the control of CMV promoter with intron A.
Flow staining for RBD trimer protein expression. HEK293 cells were transfected
with 1 µg of plasmid (DNA/RBD tri) expressing trimerized from SARS-CoV-2
RBD. Cells were harvested, initially stained with live dead marker followed by cells
were then fixed with Cytofix/cytoperm (BD Pharmingen), permeabilized with
permwash (BD Pharmingen), and intracellularly stained with anti-SARS-CoV-2
RBD antibody (40592-T62, SinoBiological). Later, donkey anti-rabbit IgG coupled
to PE (406421, BioLegend) secondary antibody was used to confirm the expression.
Protein expression and purification. Monomeric and trimeric form of RBD
proteins of SARS-CoV-2 was produced by transfecting FreeStyle 293-F cells using
plasmids DNA/RBD mono and DNA/RBD tri, respectively. Transfections were
performed according to manufacturer’s instructions (Thermo Fisher). Briefly,
FreeStyle 293-F cells were seeded at a density of 2 × 106 cells/ml in Expi293
expression medium and incubated in an orbital shaking incubator at 37 °C and 127
rpm with 8% CO2 overnight. Next day, 2.5 × 106 cells/ml were transfected using
ExpiFectamineTM 293 transfection reagent (ThermoFisher, cat. no. A14524) as per
manufacturer’s protocol. The cells were grown for 72 h at 37 °C,127 rpm, 8% CO2.
The cells were removed by centrifugation at 2000×g for 10 minutes at 4 °C, the
supernatant was collected and filtered using a 0.22 µm stericup filter (Thermo-
Fisher, cat. no. 290-4520) and loaded onto pre-equilibrated affinity column for
protein purification. The SARS-CoV-2 RBD monomer (with His tag) and RBD
trimer proteins were purified using Ni-NTA resin (ThermoFisher, cat. no. 88221)
and Agarose bound conA (Vector Labs, cat. no. AL-1243-5) respectively. Briefly,
His-Pur Ni-NTA resin was washed with PBS by centrifugation at 2000×g for 10
min. The resin was resuspended with the supernatant and incubated for 2 h on a
shaker at RT. Polypropylene column was loaded on the supernatant–resin mixture
and washed with wash buffer (25 mM Imidazole, 6.7 mM NaH2PO4·H2O, and 300
mM NaCl in PBS) four times, after which the protein was eluted in elution buffer
(235 mM Imidazole, 6.7 mM NaH2PO4·H2O and 300 mM NaCl in PBS). RBD
trimer protein supernatants were mixed with ConA Agarose-resin overnight on
rocker at 4 °C. The supernatant-resin mix was loaded onto the column and washed
three times with PBS and eluted using 1 M methyl-α-D mannopyranoside (pH 7.4).
Eluted proteins were dialyzed against PBS using Slide-A-lyzer Dialysis Cassette
(ThermoScientific, Cat# 66030) and concentrated using either 10 kDa Amicon
Centrifugal Filter Units (for RBD-mono) or 50 kDa Amicon Centrifugal Filter
Units (for RBD-tri) at 2000×g at 4 °C. The concentrated protein elutes were run on
a Superdex 200 Increase 10/300 GL (GE Healthcare) column on an AktaTMPure
(GE Healthcare) system and collected the peak that is matching to corresponding
protein. The quantity of the proteins was estimated by BCA Protein Assay Kit
(Pierce) and quality by BN-PAGE (NuPAGE™, 4–12% Bis–Tris Protein Gels,
ThermoScientific), SDS–PAGE, and Western blot. Image Lab 5.2 version software
was used to acquire images.
Western blotting. HEK293-T cells were transfected with 1 µg of plasmid (DNA/
RBD-monomer and DNA/RBD-trimer) expressing monomer and trimerized forms
of SARS-CoV-2 RBD. Cells were harvested and lysed in ice-cold RIPA buffer and
supernatants were collected. Lysates were kept on ice for 10 min, centrifuged, and
resolved by SDS–PAGE using precast 4–15% SDS polyacrylamide gels (BioRad).
Proteins were transferred to a nitrocellulose membrane, blocked with 1% casein
blocker overnight (Cat# 1610782 BioRad), and incubated for 2 h at room tem-
perature with primary RBD antibody (Cat# 40592-T62, Sino Biologicals) diluted
1:4000 in blocking buffer. The membranes were washed in PBS containing Tween-
20 (0.05%) and incubated for 1 h with horseradish peroxidase-conjugated anti-
rabbit secondary antibody (Cat #4030-05, Southern Biotech). The membranes were
washed, and proteins were visualized using the ECL select chemiluminescence
substrate (Cat# RPN2235, GE Healthcare).
Animal vaccination. BALB/c mice of 6–8-week-old female were immunized with
1–10 μg SARS-CoV-2 RBD trimer or monomer protein, intramuscularly, at weeks
0 and 4 with either aluminum hydroxide (100 µg) or Alum- 3M-052 (100 µg alum,
1 µg 3M-052). Antigen was mixed with the adjuvant and incubated at 4 °C for 15
min on a rocker before immunization. The blood samples were collected at two
weeks following each immunization by facial vein puncture in BD Microtainer®
Tube for analyzing SARS-CoV-2 RBD-specific serum antibody responses.
SARS-CoV-2 (MA10) challenge. All SARS-CoV-2 (MA10) challenge experiments
were carried out at the University of North Carolina (UNC) at Chapel Hill. Briefly,
mice were anesthetized using ketamine/xylazine and infected intranasally with 105
PFU SARS-CoV-2 MA10 strain diluted in PBS28. Briefly, the mouse-adapted SARS-
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CoV-2 virus (MA10) was generated from an infectious clone of SARS-CoV-2 MA
stock and further genetically engineered to introduce Q498Y/P499T substitutions into
the spike protein. SARS-CoV-2 MA10 stock was generated from a P10-infected mouse
lung homogenate via inoculation of Vero E6 cells. Clinical signs of disease (weight loss
and body score) were monitored daily. The mice were euthanized by isoflurane
overdose at indicated time points when samples for titer (caudal right lung lobe) were
collected. Plaque assay was used to define Lung viral titers. Briefly, right caudal lung
lobes were homogenized in 1ml PBS using glass beads and serial dilutions of the
clarified lung homogenates were added to a monolayer of Vero E6 cells. After 3 days
plaques were visualized via staining with Neutral Red dye and counted.
Rhesus macaque study. A total of 16 Indian origin rhesus macaques (Macaca
mulatta; male) from 4 to 6 years of age were included in this study. The animal
study was conducted at Yerkes National Primate Research Center, Emory Uni-
versity, and was approved by the Emory IACUC. Nine macaques were randomly
allocated into two vaccine groups. Group 1 (n= 5) received 30 µg RBD trimer
antigen adjuvanted with 1 mg amounts of Aluminum Hydroxide. Group 2 (n= 4)
received 30 µg RBD trimer antigen adjuvanted with Alum (1 mg)-3M-052 (10 µg)
formulations. Macaques were immunized intramuscularly with indicated RBD
trimer-adjuvanted vaccines, at week 0 and 4, respectively with a total volume of
1 ml in the thigh. The serum samples and PBMCs were collected at the indicated
time points and subjected to immunological assays. The remaining 7 animals were
used as controls. Of the 7, 5 animals received wild-type modified vaccinia Ankara
(MVA) vaccine as reported previously47 and 2 did not receive any vaccine.
SARS-CoV-2 challenge. 4 weeks after final immunization the macaques were
challenged with a total of 5 × 104 pfu (2.5 × 104 pfu/ml) of SARS-CoV-2 (2019-
nCoV/USA_WA1/2020). Virus was administered as 1 ml by IT and 1 ml by
intranasal (IN) route (0.5 ml in each nostril). Nasal swabs and BAL samples were
collected, stored immediately in the viral transport media, and processed for viral
RNA extraction on the same day. Starting from the day of challenge, the nasal
swabs and BAL fluid were collected on day 2, 4, 7, and 10 and subjected to viral
load measurements. At Day 10 after SARS-CoV-2 challenge, all vaccinated and
non-vaccinated macaques were euthanized. Necropsy samples were collected (lung
tissues) and were subjected to Hematoxylin and Eosin staining.
Binding antibody responses using ELISA. SARS-CoV-2 S (RBD, S1, and S)-spe-
cific IgG in serum and BAL was quantified by enzyme-linked immunosorbent assay
(ELISA)48. Briefly, Nunc high-binding ELISA plates were coated with 2 µg/ml of
recombinant SARS-CoV-2 proteins (RBD, S1, and S) proteins in Dulbecco’s
phosphate-buffered saline (DPBS) and incubated overnight at 4 °C. SARS-CoV-2 RBD
and S1 proteins were produced in the lab whereas, S1 and S (S1+ S2 ECD) proteins
were purchased. Plates were then blocked with 5% blotting-grade milk powder and 4%
whey powder in DPBS with 0.05% Tween 20 for 2 h at room temperature (RT).
Plates were then incubated with serially diluted serum samples (starting from 100, 3-
fold, 8x) and incubated for 2 h at RT followed by six washes. Total SARS-CoV-2 S
(RBD, S1, and S)-specific mouse IgG and monkey IgG antibodies were detected using
HRP-conjugated anti-mouse (1:6000) (Southern Biotech; AL, USA) and goat anti-
monkey IgG secondary antibody (1:10,000), respectively for 1 h at RT. The plates were
washed and developed using TMB (2-Component Microwell Peroxidase Substrate Kit)
and the reaction was stopped using 1 N phosphoric acid solution. Plates were read at
450 nm wavelength within 30min using a plate reader (Molecular Devices, San Jose,
CA, USA). ELISA endpoint titers were defined as the highest reciprocal serum dilution
that yielded an absorbance >2-fold over background values.
Live-virus neutralization. Live-virus SARS-CoV-2 neutralization antibodies were
assessed using a full-length mNeonGreen SARS-CoV-2 (2019-nCoV/USA_WA1/
2020), generated as previously described46. Vaccinated mice, NHP, and post-
challenge sera were incubated at 56 °C for 30 min and manually diluted in duplicate
in serum-free Dulbecco’s modified Eagle medium (DMEM) and incubated with
750–1000 focus-forming units (FFU) of infectious clone-derived SARS-CoV-2-
mNG virus46 at 37 °C for 1 h. The virus/serum mixture was added to VeroE6 cell
(C1008, ATCC, #CRL-1586) monolayers, seeded in 96-well blackout plates, and
incubated at 37 °C for 1 h. Post incubation, the inoculum was removed and
replaced with pre-warmed complete DMEM containing 0.85% methylcellulose.
Plates were incubated at 37 °C for 24 h. After 24 h, the methylcellulose overlay was
removed, cells were washed three times with phosphate-buffered saline (PBS), and
fixed with 2% paraformaldehyde (PFA) in PBS for 30 min at room temperature.
PFA is then removed and washed twice with PBS. The foci were visualized using an
ELISPOT reader (CTL ImmunoSpot S6 Universal Analyzer) under a FITC channel
and enumerated using Viridot49. Viridot has only one version but, was written to
work with versions up to R 3.4.1. This was mentioned in the details. The neu-
tralization titers were calculated as follows: 1—ratio of the (mean number of foci in
the presence of sera: foci at the highest dilution of respective sera sample). Each
specimen is tested in two independent assays performed at different times. The
focus-reduction neutralization mNeonGreen live-virus 50% titers (FRNT-mNG50)
were interpolated using a 4-parameter nonlinear regression in GraphPad Prism
8.4.3. Samples that did not neutralize at the limit of detection at 50% were plotted
at 10 and were used for geometric mean calculations.
Antibody isotype, IgG subclass, and FcR binding of mouse sera. For relative
quantification of antigen-specific antibody titers, a customized multiplexed approach
was applied, as previously described50. Therefore, magnetic microspheres with a unique
fluorescent signature (Luminex) were coupled with SARS-CoV-2 antigens including
spike protein (S) (provided by Eric Fischer, Dana Farber), RBD, and CoV HKU1 RBD
(provided by Aaron Schmidt, Ragon Institute), CoV-2 S1 and S2 (Sino Biologicals) as
well as influenza as control (Immune Tech). Coupling was performed using EDC
(Thermo Scientific) and Sulfo-NHS (Thermo Scientific) to covalently couple antigens to
the beads. 1.2 × 103 beads per region/ antigen were added to a 384-well plate (Greiner)
and incubated with diluted plasma samples (1:90 for all readouts) for 16 h while shaking
at 900 rpm at 4 °C, to facilitate immune complex formation. The next day, immune
complexed microspheres were washed three times in 0.1% BSA and 0.05% Tween-20
using an automated magnetic plate washer (Tecan). Anti-mouse IgG-, IgG2a-, IgG3-,
IgA- and IgM-PE coupled (Southern Biotech) detection antibodies were diluted in
Luminex assay buffer to 0.65 μg/ml. Beads and detection antibodies were incubated for
1 h at RT while shaking at 900 rpm. Following washing of stained immune complexes, a
tertiary goat anti-mouse IgG-PE antibody (Southern Biotech) was added and incubated
for 1 h at RT on a shaker. To assess Fc-receptor binding, mouse Fc-receptor FcγR2,
FcγR3, FcγR4 (Duke Protein Production facility) were biotinylated (Thermo Scientific)
and conjugated to Streptavidin-PE for 10min (Southern Biotech) before adding to
immune complexes and processed as described above. Finally, beads were washed and
acquired on a flow cytometer, iQue (Intellicyt) with a robot arm (PAA). Events were
gated on each bead region, median fluorescence of PE for bead positive events were
reported. Samples were run in duplicate for each secondary detection agent.
Antibody isotype, IgG subclass, and FcR binding of monkey sera. A Luminex
assay was used to detect and quantify antigen-specific subclass, isotype, and Fc-
receptor (binding) factors50. With this assay, we measured the antibody con-
centration against SARS-CoV-2 RBD (kindly provided by Aaron Schmidt, Ragon
Institute) and SARS-CoV-2 S (kindly provided by Erica Ollmann Saphire, La Jolla
Institute). Carboxylate-modified microspheres (Luminex) were activated using
EDC and Sulfo-NHS and antigens were covalently bound to the beads via NHS-
ester linkages. Antigen-coupled beads were washed and blocked. Immune com-
plexes were formed by mixing appropriately diluted plasma (1:100 for IgG1, IgG2,
IgG3, IgG4, IgA, IgM, and 1:1000 for FcγRs) to antigen-coupled beads and incu-
bating the complexes overnight at 4 °C. Immune complexes were then washed with
0.1% BSA 0.02% Tween-20. PE-coupled secondary antibodies for each antibody
isotype or subclass (Southern Biotech) were used to detect antigen-specific anti-
body titer. For FcRs, biotinylated FcRs were labeled with streptavidin-PE before
addition to immune complexes. Fluorescence was measured with an iQue (Intel-
licyt) and analyzed using Forecyt (v 8.1) software. Data are reported as median
fluorescence intensity (MFI).
ADCP, ADNP, and ADCD assays for monkey sera. ADCP, ADNP, and ADCD
were measured as previously described51–53. For ADCP and ADNP, yellow-green
fluorescent neutravidin beads were coupled to biotinylated SARS-CoV-2 S or RBD.
For ADCD, red fluorescent neutravidin beads were coupled to biotinylated SARS-
CoV-2 S or RBD. Antigen-coupled beads were then incubated with appropriately
diluted plasma (ADCP 1:100, ADNP 1:50, ADCD 1:10) for 2 h at 37 °C to form
immune complexes. For ADCP, THP-1s (ATCC) were added at 1.25 × 105 cells/ml
and incubated for 16 h at 37 °C. For ADNP, leukocytes were isolated from fresh
peripheral whole blood by lysing erythrocytes using ammonium-chloride potas-
sium lysis. Leukocytes were added to immune complexes at 2.5 × 105 cells/ml and
incubated for 1 h at 37 °C. Neutrophils were detected using anti-human CD66b
Pacblue (Biolegend). For ADCD, lyophilized guinea pig complement (Cedarlane)
was resuspended, diluted in gelatin veronal buffer with calcium and magnesium
(GVB++, Boston BioProducts), and added to immune complexes. The deposition
of C3 was detected using an anti-C3 FITC antibody (Mpbio).
All functional assays were acquired with an iQue (Inellicyt) and analyzed using
Forecyt software. For ADCP, events were gated on singlets and fluorescent cells.
For ADNP, bead-positive neutrophils were defined as CD66b positive, fluorescent
cells. For both ADCP and ADNP, a phagocytic score was defined as (percentage of
bead-positive cells) × (MFI of bead-positive cells) divided by 10,000. For ADCD,
data were reported as median fluorescence of C3 deposition (MFI).
Cell processing. For mouse studies, spleens and lungs of vaccinated and control
animals were removed and placed on ice in cold RPMI 1640 (1×) with 5% FBS
(Company, state, USA). 1× β-Mercaptoethanol (Invitrogen, State, USA) was added
to the complete medium to isolate splenocytes. Whereas lungs were cut into small
pieces and incubated at 37 °C in RPMI (1×) medium containing Collagenase type
IV and DNase I with gentle shaking for 30 min. After incubation, cells were isolated
by forcing tissue suspensions through a 70 µM cell strainer. RBCs were removed by
ACK lysis buffer and live cells counted by trypan blue exclusion. For macaques,
PBMC from blood collected in sodium citrate CPT tubes was isolated using
standard procedures. Post SARS-CoV-2 challenge, samples were processed and
stained in BSL-3 facility.
For BAL fluid processing and single-cell isolation, up to 50 ml physiological
saline was delivered through the trachea into the lungs of anesthetized animals
using a camera-enabled fiberoptic bronchoscope. The flushed saline was re-
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aspirated five times before pulling out the bronchoscope. This collection was
filtered through 70 μm cell strainer and centrifuged at 1126×g for 5 min. Pelleted
cells were suspended in 1 ml R10 medium (RPMI(1×), 10% FBS) and stained as
described in the sections below.
For processing lymph-node, lymph-node biopsies were dissociated using 70 μm
cell strainer. The cell suspension was washed twice with R-10 media.
Intracellular cytokine staining (ICS). Functional responses of SARS-CoV-2 RBD,
S1 and S2 specific CD8+ and CD4+ T cells in vaccinated animals were measured
using peptide pools and intracellular cytokine staining (ICS) assay54. Overlapping
peptides (13 or 17 mers overlapping by 10 amino acids) were obtained from BEI
resources (NR-52402 for spike and NR-52419 for NC) and different pools (S1, S2,
RBD, and NC) were made. The S1 pool contained peptides mixed from 1 to 97, S2
pool contained peptides mixed from 98 to 181, RBD pool contained peptides 46–76
and NC pool contained 57 peptides. Each peptide was used at 1 μg/ml con-
centration in the stimulation reaction. Two million cells suspended in 200 μl of
RPMI 1640 medium with 10% FBS were stimulated with 1 μg/ml CD28 (BD
Biosciences), 1 μg/ml CD49d (BD Biosciences) co-stimulatory antibodies, and
different peptide pools. These stimulated cells were incubated at 37 °C in 5% CO2-
conditioned incubator. After 2 h of incubation, 1 μl Golgi-plug and 1 μl Golgi-stop/
ml (both from BD Biosciences) were added and incubated for 4 more hours. After
total 6 h of incubation, cells were transferred to 4 °C overnight and were stained the
next day. Cells were washed once with FACS wash (1XPBS, 2% FBS, and 0.05%
sodium azide) and surface stained with Live/Dead-APC-Cy7, anti-CD3, anti-CD4,
and anti-CD8, each conjugated to a different fluorochrome for 30 min at RT. The
stained cells were washed once with FACS wash and permeabilized with 200 μl of
cytofix/cytoperm for 30 min at 4 °C. Cells were washed once with perm wash and
incubated with anti-cytokine antibodies for 30 min at 4 °C. Finally, the samples
were washed once with perm wash and once with FACS wash, and fixed in 4%
paraformaldehyde solution for 20 min before acquiring on BD LSR Fortessa flow
cytometer (v8.0.1). Data were analyzed using FlowJo software.
Histopathological examination. For histopathologic examination in macaques, the
animals were euthanized due to the study endpoint, and a complete necropsy was
performed. For histopathologic examination, various tissue samples including lung,
nasal turbinates, trachea, tonsils, hilar lymph nodes, spleen, heart, brain, gastro-
intestinal tract (stomach, jejunum, ileum, colon, and rectum), testes were fixed in 10%
neutral-buffered formalin for 24 h at room temperature, routinely processed, paraffin-
embedded, sectioned at 4 µm, and stained with hematoxylin and eosin (H&E). The
H&E slides from all tissues were examined by two board-certified veterinary pathol-
ogists. For each animal, all the lung lobes were used for analysis, and affected
microscopic fields were scored semiquantitatively as Grade 0 (None); Grade 1 (Mild);
Grade 2 (Moderate); and Grade 3 (Severe). Scoring was performed based on these
criteria: number of lung lobes affected, type 2 pneumocyte hyperplasia, alveolar septal
thickening, fibrosis, perivascular cuffing, peribronchiolar hyperplasia, inflammatory
infiltrates, hyaline membrane formation. An average lung lobe score was calculated by
combining scores from each criterion. For animals with multiple affected lung lobes,
each lung lobe was assessed individually and then the scores for each category were
averaged. The total score was then determined for each animal. Digital images of H&E
stained slides were captured at ×100 and ×200 magnification with an Olympus BX43
microscope equipped with a digital camera (DP27, Olympus) using Cellsens® Standard
2.3 digital imaging software (Olympus).
Immunophenotyping of BAL and LN cells. Briefly, the cells were stained with a
surface antibody cocktail and incubated at RT for 30 min. The stained cells were
given a FACS wash and permeabilized with 1 ml perm buffer (Invitrogen) for 30
min at RT. These cells were given a perm wash (Invitrogen) and stained with an
intracellular antibody cocktail for 30 min at RT. Finally, the cells were washed once
with perm wash and a FACS wash and fixed in 4% paraformaldehyde solution for
20 min before acquiring on BD LSR-II flow cytometer (v8.0.1). Samples prior to the
challenge were acquired without 20-min 4% paraformaldehyde fixation.
BAL innate cell surface antibody cocktail: live/dead stain-APC-Cy7, anti-CD3-
BV605, anti-CD20-BV605, anti-NKG2A-APC, anti-HLADR-PERCP, anti-CD11b-
PE/Dazzle 594, anti-163-eFlour-450, anti-CD123-PE-Cy7, anti-CD11c-BV655, and
anti-BDCA1-BV711. BAL innate cell intracellular antibody: anti-Ki67-BV786. T-
cell phenotype surface antibody cocktail: live/dead stain-APC-Cy7, anti-CD3-
PerCP, anti-CD4-BV655, anti-CD8-BV711, anti-PD1-BV421, anti-CXCR5-PE, and
anti-CXCR3-BV605. T-cell phenotype intracellular antibody: anti-Ki67-BV786. B-
Cell phenotype surface antibody cocktail: live/dead stain-APC-Cy7, anti-CD3-
AF700, and anti-CD20-BV605, B-cell phenotype intracellular antibody: anti-BCL6-
PE-CF594 and anti-Ki67-PE-Cy7.
Viral RNA extraction and quantification. SARS-CoV-2 genomic and subgenomic
RNA was quantified in naso-pharyngeal (NP) swabs, and brocho-alveolar lavages
(BAL). Swabs were placed in 1 ml of Viral Transport Medium (VTM; Labscoop
(VR2019-1L)). Viral RNA was extracted from NP swabs, throat swabs, and BAL on
fresh specimens using the QiaAmp Viral RNA mini kit according to the manu-
facturer’s protocol. Quantitative PCR (qPCR) was performed on subgenomic using
primer and probe align the subgenomic mRNA transcript of the E gene55 are
SGMRNA-E-F: 5′-CGATCTCTTGTAGATCTGTTCTC-3′, SGMRNA-E-R: 5′-
ATATTGCAGCAGTACGCACACA-3′, and SGMRNA-E-Pr: 5′-FAM-ACACTA
GCCATCCTTACTGCGCTTCG-3′ (Table S2). qPCR reactions were performed in
duplicate with the Thermo-Fisher 1-Step Fast virus master mix using the manu-
facturer’s cycling conditions, 200 nM of each primer, and 125 nM of the probe. The
limit of detection in this assay was about 128 copies per ml of VTM/BAL
depending on the volume of extracted RNA available for each assay. To verify
sample quality the CDC RNase P p30 subunit qPCR was modified to account for
rhesus macaque specific polymorphisms. The primer and probe sequences are RM-
RPP30-F 5′-AGACTTGGACGTGCGAGCG-3′, RM-RPP30-R 5′- GAGCCGCTGT
CTCCACAAGT-3′, and RPP30-Pr 5′-FAM-TTCTGACCTGAAGGCTCTGCGC
G-BHQ1-3′56. A single well from each extraction was run as described above to
verify RNA integrity and sample quality via detectable and consistent cycle
threshold values (Ct between 25 and 32).
Quantification and statistical analysis. GraphPad Prism version 8.4.3 (471)
(GraphPad Software) was used to perform data analysis and statistics. The difference
between any two groups at a time point was measured either using a two-tailed
nonparametric Mann–Whitney rank-sum test or unpaired parametric t-test
depending on the distribution of the data. Comparisons between different time points
within a group used paired parametric t-test. P-value of <0.05 was considered sig-
nificant. The correlation analysis was performed using the Spearman rank test.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
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